The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Future directions in AML: targeted therapies, antibody-radiation conjugates & new combinations
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the future of acute myeloid leukemia (AML) treatment in a time when numerous novel agents are showing promise in early phase trials. Dr Fathi comments that, while several therapeutics with unique mechanisms of action appear propitious, mature data is needed before conclusions can be drawn. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
